参考文献/References:
[1] WANG Guocan, ZHAO Di, SPRING D J,et al.Geneticsand biology of prostate cancer[J].GenesDev,2018,32(17/18):1105-1140.
[2] 高瑞松, 周青, 张晓波, 等. 湖南部分地区2877 例前列腺癌患者临床流行病学特征及流行学趋势分析[J]. 中华男科学杂志,2020,26(4):309-315.GAO Ruisong, ZHOU Qing, ZHANG Xiaobo, et al.Clinical features and epidemiological trend of prostatecancer in the Changsha area of Hunan Province: Analysisof 2 877 cases[J].National Journal of Andrology,2020,26(4):309-315.
[3] 苏欢, 陈明. 炎症反应与肿瘤微环境对前列腺癌作用机制的研究进展[J]. 东南大学学报（ 医学版）,2017,36(5):847-851.SU Huan, CHEN Ming. Research progress on themechanism of inflammatory response and tumormicroenvironment on prostate cancer[J].J SoutheastUniv(Med Sci Edi), 2017,36(5):847-851.
[4] MCGEACHY M J,CUA D J, GAFFEN S L.The IL-17family of cytokines in health and disease[J]. Immunity.2019,50(4):892-906.
[5] WANG Ke, LIU Jiaming, LI Jiansheng. IL-35-producing B cells in gastric cancer patients. Medicine(Baltimore). 2018,97(19):e0710.
[6] PLOUSSARD G, STAERMAN F, PIER-REVELCINJ, et al. Predictive factors of oncologic outcomes inpatients who do not achieve undetectable prostatespecific antigen after radical prostatectomy[J]. TheJournal of urology, 2013, 190(5);1750-1756.
[7] SINGH N, BABY D,RAJGURU J P, et al.Inflammationand cancer[J].Ann Afr Med,2019,18(3):121-126.
[8] YANG Keqin, LIU Yan, HUANG Qinghua, et al. Bonemarrow-derived mesenchymal stem cells inducedby inflammatory cytokines produce angiogeneticfactors and promote prostate cancer growth[J].BMCCancer,2017,17(1):878.
[9] CHEN Dandan,TANG Ping, LIU Linxiang, et al. Bonemarrow-derived mesenchymal stem cells promote cellproliferation of multiple myeloma through inhibitingT cell immune responses via PD-1/PD-L1 pathway[J].Cell Cycle,2018,17(7):858-867.
[10] PORTER C M, SHRESTHA E,PEIFFER L B,et al.Themicrobiome in prostate inflammation and prostatecancer[J].Prostate Cancer Prostatic Dis,2018,21(3):345-354.
[11] RICH H E, ALCORN J F.IL-17 strikes a chord inchronic obstructive pulmonary disease exacerbation[J].Am J Respir Cell Mol Biol,2018,58(6):669-670.
[12] SONG Yang, YANG Jianming. Role of interleukin(IL)-17 and T-helper (Th)17 cells in cancer[J].BiochemBiophys Res Commun,2017,493(1):1-8.
[13] 徐锐, 王莉, 李满祥. 白细胞介素-17 在前列腺癌组织中的表达及临床意义[J]. 宁夏医科大学学报,2017,39(7):756-759.XU Rui,WANG Li, LI Manxiang. Expression andclinical significance of interleukin-17 in prostatticcancer[J].Journal of Ningxia Medical University,2017,39(7):756-759.
[14] WANG Xun, YANG Lingyun, HUANG Feng, et al.Inflammatory cytokines IL-17 and TNF-α up-regulatePD-L1 expression in human prostate and colon cancercells[J].Immunol Lett,2017,184:7-14.
[15] GUO Na, SHEN Ge, ZHANG Ying,et al. Interleukin-17promotes migration and invasion of human cancer cellsthrough upregulation of MTA1 Expression[J].FrontOncol,2019,9:546.
[16] CHEN Chong, ZHANG Qiuyang, LIU Sen, et al. IL-17 and insulin/IGF1 enhance adhesion of prostatecancer cells to vascular endothelial cells through CD44-VCAM-1 interaction[J].Prostate,2015,75(8):883-895.
[17] TEYMOURI M,PIRRO M,FALLARINO F,et al.IL-35,a hallmark of immune-regulation in cancer progression,chronic infections and inflammatory diseases[J].Int JCancer,2018,143(9):2105-2115.
[18] FRIEDMAN A, LIAO K L.The role of the cytokinesIL-27 and IL-35 in cancer[J].Math Biosci Eng,2015,12(6):1203-1217.
[19] LEE C C, LIN J C, HWANG W L,et al.Macrophagesecretedinterleukin-35 regulates cancer cellplasticity to facilitate metastatic colonization[J].NatCommun,2018,9(1):3763.
[20] ZHANG Jian, MAO Tao, WANG Shuyun, et al. Interleukin-35 expression is associated with colon cancerprogression[J].Oncotarget,2017,8(42):71563-71573.
[21] ZHU Jialin, YANG Xueling, WANG Yan, et al.Interleukin-35 is associated with the tumorigenesis and progressionof prostate cancer[J].Oncol Lett,2019,17(6):5094-5102.
[22] OLSON B M, JANKOWSKA-GAN E, BECKER J T,etal. Human prostate tumor antigen-specific CD8+ regulatoryT cells are inhibited by CTLA-4 or IL-35 blockade[J].J Immunol,2012,189(12):5590-601.
相似文献/References:
[1]李腾达a,司 宇a,刘 鹏a,等.Gas6在免疫性血小板减少症患者中表达增高及临床意义[J].现代检验医学杂志,2017,32(03):37.[doi:10.3969/j.issn.1671-7414.2017.03.010]
LI Teng-daa,SI Yua,LIU Penga,et al.Increased Expression of Gas6 in Patients
with Immune Thrombocytopenia and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(04):37.[doi:10.3969/j.issn.1671-7414.2017.03.010]
[2]杨依骏,杜建钢,朱琴芳,等.系统性红斑狼疮患者血清IL-10和IL-17水平检测的临床意义[J].现代检验医学杂志,2017,32(03):71.[doi:10.3969/j.issn.1671-7414.2017.03.019]
YANG Yi-jun,DU Jian-gang,ZHU Qin-fang,et al.Clinical Significance of Serum IL-10 and IL-17
in Patients with Systemic Lupus Erythematosus[J].Journal of Modern Laboratory Medicine,2017,32(04):71.[doi:10.3969/j.issn.1671-7414.2017.03.019]
[3]陈志勇a,罗世林a,张 健b,等.慢阻肺患者血清IL-17，IL-27和IL-33水平表达及与不同临床分期FeNO和肺功能的相关性研究[J].现代检验医学杂志,2021,36(04):152.[doi:10.3969/j.issn.1671-7414.2021.04.033]
CHEN Zhi-yonga,LUO Shi-lina,ZHANG Jianb,et al.Expression of Serum IL-17, IL-27 and IL-33 in Patients with ChronicObstructive Pulmonary Disease and Its Correlation with FeNO and LungFunction in Different Clinical Stages[J].Journal of Modern Laboratory Medicine,2021,36(04):152.[doi:10.3969/j.issn.1671-7414.2021.04.033]
[4]梁 津,刘轾彬,梁成员,等.初诊活动性肺结核患者血浆IL-6，IL-17，IL-37及TIM-3水平表达及其临床意义[J].现代检验医学杂志,2021,36(06):179.[doi:10.3969/j.issn.1671-7414.2021.06.039]
LIANG Jin,LIU Zhi-bin,LIANG Cheng-yuan,et al.Expression and Clinical Significance of Plasma IL-6, IL-17, IL-37 and TIM-3 in Patients with Newly Diagnosed Active Pulmonary Tuberculosis[J].Journal of Modern Laboratory Medicine,2021,36(04):179.[doi:10.3969/j.issn.1671-7414.2021.06.039]
[5]罗 文,罗 钢,周玉玲,等.Graves 病患者血清IL-23，IL-17 及Klotho 蛋白水平变化及意义[J].现代检验医学杂志,2022,37(04):178.[doi:10.3969/j.issn.1671-7414.2022.04.035]
LUO Wen,LUO Gang,ZHOU Yu-ling,et al.Changes of Serum IL-23，IL-17 and Klotho Protein Levels in Patients with Graves Disease[J].Journal of Modern Laboratory Medicine,2022,37(04):178.[doi:10.3969/j.issn.1671-7414.2022.04.035]